Two Sigma Advisers LP Has $932,000 Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Two Sigma Advisers LP grew its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 35.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 87,500 shares of the company's stock after purchasing an additional 23,000 shares during the period. Two Sigma Advisers LP owned 0.05% of Certara worth $932,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Blue Trust Inc. raised its holdings in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after purchasing an additional 823 shares during the period. Wells Fargo & Company MN grew its position in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the last quarter. Bank of Montreal Can grew its position in shares of Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after acquiring an additional 1,670 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in shares of Certara by 20.5% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock worth $138,000 after acquiring an additional 2,202 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CERT has been the subject of several recent research reports. Stephens restated an "overweight" rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Robert W. Baird boosted their target price on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. KeyCorp boosted their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Finally, TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Price Performance

NASDAQ CERT traded down $0.25 on Thursday, hitting $11.70. 1,329,055 shares of the company were exchanged, compared to its average volume of 1,355,236. The firm has a 50 day moving average of $11.98 and a two-hundred day moving average of $11.82. The company has a market cap of $1.90 billion, a P/E ratio of -58.50, a P/E/G ratio of 9.29 and a beta of 1.44. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $17.40.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter in the prior year, the company earned $0.10 EPS. The firm's quarterly revenue was up 9.7% on a year-over-year basis. On average, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.